Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
13 September 2019Website:
http://www.cybin.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:59:58 GMTDividend
Analysts recommendations
Institutional Ownership
CYBN Latest News
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended March 31, 2024, and recent business highlights. “I am proud of the swift and meaningful progress we have made advancing our two lead programs – C.
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024. Mr. Drysdale's.
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin's prop.
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin's Chief Medical Officer, and Ellen James, Ph.D., Cybin's Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic.
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024. The Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development.
Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will participate in a panel discussion titled “Emerging Therapeutic Candidates for Mental Health” at.
What type of business is Cybin?
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
What sector is Cybin in?
Cybin is in the Healthcare sector
What industry is Cybin in?
Cybin is in the Biotechnology industry
What country is Cybin from?
Cybin is headquartered in Canada
When did Cybin go public?
Cybin initial public offering (IPO) was on 13 September 2019
What is Cybin website?
https://www.cybin.com
Is Cybin in the S&P 500?
No, Cybin is not included in the S&P 500 index
Is Cybin in the NASDAQ 100?
No, Cybin is not included in the NASDAQ 100 index
Is Cybin in the Dow Jones?
No, Cybin is not included in the Dow Jones index
When does Cybin report earnings?
Next earnings report date is not announced yet